SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 analyses of Verastems avutometinib/defactinib combination in recurrent low-grade serous ovarian cancer are drawing interest, particularly the reported activity in KRAS wild-type patients and whether it could broaden the treatment opportunity. Traders are also focused on the planned VS-7375 KRAS G12D update across several cancers, weighing its potential against competing drugs and the need for convincing efficacy and tolerability data.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

A Morpheus Research short report and concerns about Fervos geothermal performanceincluding water loss and transmission constraintsare fueling debate amid the stocks sharp post-IPO decline. Bears question whether the technology and economics will scale, while bulls point to Cape Stations first power and the Google power agreement as evidence of commercial progress.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and breakout on heavy volume has sparked bullish momentum chatter alongside concerns about profit-taking and whether support will hold. Traders link renewed interest to Starknets consideration of an independent L1 transition and its quantum-resistance, privacy, and Bitcoin DeFi ambitions, though the L1 shift remains a possibility rather than a completed change.

TOSHI

Speculation about a technical rebound is driving attention, with bulls pointing to accumulation, rising volume and a possible short squeeze as TOSHI repeatedly tests resistance. Skeptics counter that prior breakout attempts have faded and the token remains under pressure; no confirmed new catalyst dominates the discussion.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinet is drawing attention after reaching a fresh 52-week high amid strength in cybersecurity stocks, as traders view AI-related security risks as a tailwind for the sector. The bullish momentum is tempered by concerns about stretched valuations and the breakouts light volume, with some traders warning of exhaustion or a pullback.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

XLV is drawing attention after bouncing from widely discussed technical support, with traders highlighting a bullish reversal and potential continuation higher. Some remain cautious about further pullbacks and mixed sector momentum, so the bullish view is not unanimous.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention mainly for technical price action, with repeated chart commentary describing consolidation and a neutral setup. Traders are split between expecting a bounce and calling the coin weak, while broader crypto-cycle optimism also appears but no specific catalyst dominates.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

The FDAs acceptance of Intellias lonvo-z application for priority review, with a decision date set for March 2027 and no advisory committee planned, is the main catalyst. Traders see it as a step toward a potential HAE launch, while others point to financing and commercialization risks and question why the shares have not responded more strongly.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa is the main focus, with traders watching for FDA acceptance and a review timeline. The reaction is divided: some view the filing and clinical data as de-risking steps, while others point to prior IZAR disappointment, management concerns and uncertainty over commercialization or a buyout to explain the muted sentiment.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Positive clinical data for Kyvernas miv-cel in stiff person syndrome and generalized myasthenia gravis, alongside progress toward an SPS BLA, is driving attention. Traders are weighing the therapys durability and safety against a sharp, volatile post-data reaction, with some attributing the pullback to profit-taking and potential dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

5 Dividend ETFs Beating the S&P 500 This Year

Five dividend ETFs -- DFJ, SCHD, FDL, HDV and EYLD -- have outpaced SPY in 2026 as investors rotate toward quality income plays.

iShares Trust - iShares Core High Dividend ETF

AT&T Stock Gains Pre-Market After Wireless Subscriber Additions Tops Estimates: Retail Mood Lifts

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

HDV iShares Core High Dividend ETF

Fundamentals

Latest HDV News